Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Baxter
AstraZeneca
Dow
Mallinckrodt

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,351,834

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,351,834
Title:.omega.-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Abstract:This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
Inventor(s): Riedl; Bernd (Wuppertal, DE), Dumas; Jacques (Orange, CT), Khire; Uday (Hamden, CT), Lowinger; Timothy (Hyogo, JP), Scott; William (Guilford, CT), Smith; Roger A. (Madison, CT), Wood; Jill E. (Hamden, CT), Monahan; Mary-Katherine (Hamden, CT), Natero; Reina (Hamden, CT), Renick; Joel (Milford, CT), Sibley; Robert (North Haven, CT)
Assignee: Bayer Pharmaceuticals Corporation (West Haven, CT)
Application Number:09/889,227
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,351,834
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 7,351,834

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare NEXAVAR sorafenib tosylate TABLET;ORAL 021923-001 Dec 20, 2005 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,351,834

PCT Information
PCT FiledJanuary 12, 2000PCT Application Number:PCT/US00/00648
PCT Publication Date:July 20, 2000PCT Publication Number: WO00/42012

International Family Members for US Patent 7,351,834

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 035310   Start Trial
Argentina 077485   Start Trial
Austria 321027   Start Trial
Austria 460398   Start Trial
Austria 520663   Start Trial
Austria 538794   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Baxter
Express Scripts
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.